目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.2 SEGMENTAL MARKET ASSESSMENT
2.3 MARKET GROWTH RATE PROJECTION
2.3.1 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN FLOW CYTOMETRY MARKET
4.2 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY
4.3 FLOW CYTOMETRY MARKET SHARE, BY END USER, 2024
4.4 FLOW CYTOMETRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increase in demand for flow cytometry in oncology research & diagnostics
5.2.1.2 Growing use of flow cytometry in regenerative medicines
5.2.1.3 Increasing collaborations, strategic partnerships, and alliances among key players
5.2.1.4 Launch of technologically advanced flow cytometry products
5.2.2 RESTRAINTS
5.2.2.1 High cost of advanced flow cytometers (analyzers & cell sorters)
5.2.3 OPPORTUNITIES
5.2.3.1 Increased use in clinical applications and infectious disease diagnostics
5.2.4 CHALLENGES
5.2.4.1 Complexities related to reagent development
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF FLOW CYTOMETRY PRODUCTS, BY KEY PLAYER, 2022-2024
5.4.2 AVERAGE SELLING PRICE TREND OF FLOW CYTOMETRY PRODUCTS, BY REGION, 2022-2024
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 INSTRUMENT & SOFTWARE PROVIDERS
5.6.2 REAGENT & CONSUMABLE PROVIDERS
5.6.3 END USERS
5.6.4 REGULATORY BODIES
5.7 REGULATORY ANALYSIS
5.7.1 REGULATORY LANDSCAPE
5.7.1.1 Stringent FDA requirements
5.7.1.2 Analyte-specific reagent rules
5.7.1.3 Limitations in validation protocols for cell-based assays
5.7.1.4 Absence of test guidelines for cell-based fluorescence assays
5.7.1.5 IVD CE mark approvals
5.7.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2.1 North America: List of regulatory bodies, government agencies, and other organizations
5.7.2.2 Europe: List of regulatory bodies, government agencies, and other organizations
5.7.2.3 Asia Pacific: List of regulatory bodies, government agencies, and other organizations
5.7.2.4 Latin America: List of regulatory bodies, government agencies, and other organizations
5.7.2.5 Middle East & Africa: List of regulatory bodies, government agencies, and other organizations
5.8 PORTER'S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.9.2 KEY BUYING CRITERIA
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Spectral flow cytometry
5.10.1.2 Mass cytometry
5.10.1.3 Imaging flow cytometry
5.10.2 ADJACENT TECHNOLOGIES
5.10.2.1 Single-cell RNA sequencing
5.10.2.2 Microfluidics
5.10.2.3 High-content screening
5.10.3 COMPLEMENTARY TECHNOLOGIES
5.10.3.1 Single-cell analysis
5.10.3.2 Spatial analysis
5.11 PATENT ANALYSIS
5.11.1 METHODOLOGY
5.11.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
5.12 TRADE DATA ANALYSIS
5.12.1 IMPORT DATA
5.12.2 EXPORT DATA
5.13 INVESTMENT AND FUNDING SCENARIO
5.14 KEY CONFERENCES AND EVENTS, 2025-2026
5.15 IMPACT OF 2025 US TARIFF: FLOW CYTOMETRY MARKET
5.15.1 KEY TARIFF RATES
5.15.2 PRICE IMPACT ANALYSIS
5.15.3 KEY IMPACTS ON VARIOUS REGIONS
5.15.3.1 US
5.15.3.2 Europe
5.15.3.3 Asia Pacific
5.15.4 END-USE INDUSTRY IMPACT
5.15.4.1 Pharmaceutical and biotech companies
5.15.4.2 Hospitals & clinical laboratories
5.15.4.3 Academic & research institutes
5.16 IMPACT OF AI/GEN AI ON FLOW CYTOMETRY MARKET
5.16.1 MARKET POTENTIAL OF AI IN FLOW CYTOMETRY
5.16.2 AI USE CASES
5.16.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.16.4 FUTURE OF AI/GEN AI IN FLOW CYTOMETRY MARKET

6 FLOW CYTOMETRY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 REAGENTS & CONSUMABLES
6.2.1 ANTIBODIES
6.2.1.1 Increasing demand for high-specificity antibodies to propel market growth
6.2.2 ASSAYS & KITS
6.2.2.1 Need for high-precision diagnosis and advancements in personalized medicines to aid market growth
6.2.3 OTHER REAGENTS & CONSUMABLES
6.3 INSTRUMENTS
6.3.1 CELL ANALYZERS
6.3.1.1 High-range cell analyzers
6.3.1.1.1 Better sensitivity, accuracy, and flexibility in designing multicolor experiments to augment segment growth
6.3.1.2 Mid-range cell analyzers
6.3.1.2.1 Availability of compact and high-performance analyzers to support market growth
6.3.1.3 Low-range cell analyzers
6.3.1.3.1 Cost-effectiveness and increased commercialization by manufacturers to drive segment
6.3.2 CELL SORTERS
6.3.2.1 High-range cell sorters
6.3.2.1.1 High cost and budget constraints among end users to limit market growth
6.3.2.2 Mid-range cell sorters
6.3.2.2.1 Cost-effectiveness and high availability to spur market growth
6.3.2.3 Low-range cell sorters
6.3.2.3.1 Increasing commercialization in small-scale laboratories and research facilities to fuel market growth
6.4 SERVICES
6.4.1 RISING FOCUS ON WORKFLOW CONTINUITY AND PERFORMANCE MAXIMIZATION TO BOOST MARKET GROWTH
6.5 SOFTWARE
6.5.1 INCREASING AVAILABILITY OF DATA ANALYSIS SOFTWARE TO AID MARKET GROWTH
6.6 ACCESSORIES
6.6.1 HIGH AVAILABILITY OF ADVANCED AND CUSTOMIZED ACCESSORIES TO SUPPORT MARKET GROWTH

7 FLOW CYTOMETRY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 CELL-BASED FLOW CYTOMETRY
7.2.1 INCREASED FOCUS ON R&D AND TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET GROWTH
7.3 BEAD-BASED FLOW CYTOMETRY
7.3.1 HIGHER RELIABILITY AND BETTER MEASUREMENT CONSISTENCIES TO SUPPORT MARKET GROWTH

8 FLOW CYTOMETRY MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 RESEARCH APPLICATIONS
8.2.1 DRUG DISCOVERY AND DEVELOPMENT
8.2.1.1 Drug discovery
8.2.1.1.1 Growing use of phenotypic cell-based assays to support market growth
8.2.1.2 Stem cell research
8.2.1.2.1 Increasing R&D and rising investments for advanced stem cell development to drive segment
8.2.1.3 In vitro toxicity testing
8.2.1.3.1 Focus on continuous drug development by pharmaceutical & biotechnology companies to aid segment growth
8.2.2 IMMUNOLOGY
8.2.2.1 Growing prevalence of chronic autoimmune diseases to drive market
8.2.3 CELL SORTING
8.2.3.1 Increasing focus on cell-based research activities to fuel market growth
8.2.4 APOPTOSIS
8.2.4.1 Increased use in research activities to drive segment
8.2.5 CELL CYCLE ANALYSIS
8.2.5.1 High accuracy of cytometry products in cell analysis to propel segment growth
8.2.6 CELL VIABILITY
8.2.6.1 Growing use of cell viability assays in research to support market growth
8.2.7 CELL COUNTING
8.2.7.1 Rising need for multi-parametric cellular assessments to spur market growth
8.2.8 OTHER RESEARCH APPLICATIONS
8.3 CLINICAL APPLICATIONS
8.3.1 CANCER DIAGNOSTICS
8.3.1.1 Increasing prevalence of cancer to drive segment
8.3.2 HEMATOLOGY
8.3.2.1 Multi-parametric approach and high-speed cell analyzing capabilities to augment segment growth
8.3.3 AUTOIMMUNE DISEASES
8.3.3.1 Growing focus on developing treatments for autoimmune diseases to drive segment
8.3.4 ORGAN TRANSPLANTATION
8.3.4.1 Rising number of organ transplants to propel market growth
8.3.5 OTHER CLINICAL APPLICATIONS
8.4 INDUSTRIAL APPLICATIONS
8.4.1 INCREASING USE IN FOOD, DAIRY, ENERGY, AND MICROBIAL INDUSTRIES TO SUPPORT MARKET GROWTH

9 FLOW CYTOMETRY MARKET, BY END USER
9.1 INTRODUCTION
9.2 ACADEMIC & RESEARCH INSTITUTES
9.2.1 RISING PUBLIC-PRIVATE FUNDING AND INCREASING CANCER RESEARCH PROJECTS TO DRIVE MARKET
9.3 HOSPITALS & CLINICAL TESTING LABORATORIES
9.3.1 GROWING DEMAND FOR EFFECTIVE DISEASE DIAGNOSIS AND TREATMENT TO SPUR MARKET GROWTH
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 INCREASING FOCUS ON PERSONALIZED MEDICINE AND TARGETED THERAPIES TO FUEL MARKET GROWTH

10 FLOW CYTOMETRY MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK
10.2.2 US
10.2.2.1 US to dominate North American flow cytometry market during study period
10.2.3 CANADA
10.2.3.1 Ongoing government initiatives for life science research and high incidence of cancer to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK
10.3.2 GERMANY
10.3.2.1 Increasing public and private funding for advanced cell-based research activities to aid market growth
10.3.3 UK
10.3.3.1 Growing acceptance of flow cytometry-based diagnostic techniques by healthcare professionals to spur market growth
10.3.4 FRANCE
10.3.4.1 Increasing government funding for proteomics and genomics research to fuel market growth
10.3.5 ITALY
10.3.5.1 Large geriatric population and presence of well-developed healthcare system to boost market growth
10.3.6 SPAIN
10.3.6.1 High incidence of cancer and focus on translational and personalized medicines to augment market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK
10.4.2 CHINA
10.4.2.1 High incidence of cancer and favorable government policies to support market growth
10.4.3 JAPAN
10.4.3.1 Technological advancements and high prevalence of chronic diseases to drive market
10.4.4 INDIA
10.4.4.1 Rising government funding for proteomics research to drive market
10.4.5 AUSTRALIA
10.4.5.1 Increasing government research funding and growing prevalence of cancer to propel market growth
10.4.6 SOUTH KOREA
10.4.6.1 Rising number of conferences and growing focus on medical research to spur market growth
10.4.7 SINGAPORE
10.4.7.1 Increasing availability of data analysis software and growing focus on medical tourism to drive market
10.4.8 INDONESIA
10.4.8.1 Rising prevalence of HIV and cancer to drive market
10.4.9 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK
10.5.2 BRAZIL
10.5.2.1 Presence of key market players and increased emphasis on cancer research to boost market growth
10.5.3 MEXICO
10.5.3.1 Favorable trade agreements and growth of pharmaceutical industry to fuel market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Growing prevalence of chronic diseases and increasing R&D investments to boost market growth
10.6.2.2 UAE
10.6.2.2.1 Increased R&D investment and favorable government healthcare policies to drive market
10.6.2.3 Rest of GCC countries
10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 INCREASING BURDEN OF INFECTIOUS AND NON-COMMUNICABLE DISEASES TO PROPEL MARKET GROWTH
10.7.2 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN FLOW CYTOMETRY MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Product & service footprint
11.5.5.3 Region footprint
11.5.5.4 Application footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.7 VALUATION & FINANCIAL METRICS
11.7.1 VALUATION OF KEY PLAYERS
11.7.2 FINANCIAL METRICS OF KEY PLAYERS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 BECTON, DICKINSON AND COMPANY
12.1.1.1 Business overview
12.1.1.2 Products/Services offered
12.1.1.3 Recent developments
12.1.1.3.1 Product launches
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 DANAHER CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products/Services offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches
12.1.2.3.2 Deals
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 THERMO FISHER SCIENTIFIC INC.
12.1.3.1 Business overview
12.1.3.2 Products/Services offered
12.1.3.3 Recent developments
12.1.3.3.1 Product launches
12.1.3.3.2 Deals
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 AGILENT TECHNOLOGIES, INC.
12.1.4.1 Business overview
12.1.4.2 Products/Services offered
12.1.4.3 Recent developments
12.1.4.3.1 Product launches
12.1.5 SONY CORPORATION
12.1.5.1 Business overview
12.1.5.2 Products/Services offered
12.1.5.3 Recent developments
12.1.5.3.1 Product launches
12.1.5.3.2 Deals
12.1.6 BIO-RAD LABORATORIES, INC.
12.1.6.1 Business overview
12.1.6.2 Products/Services/Solutions offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches
12.1.7 MILTENYI BIOTEC
12.1.7.1 Business overview
12.1.7.2 Products/Services offered
12.1.8 ENZO BIOCHEM INC.
12.1.8.1 Business overview
12.1.8.2 Products/Services offered
12.1.9 SYSMEX CORPORATION
12.1.9.1 Business overview
12.1.9.2 Products/Services offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches
12.1.10 CYTEK BIOSCIENCES
12.1.10.1 Business overview
12.1.10.2 Products/Services offered
12.1.10.3 Recent developments
12.1.10.3.1 Product launches
12.1.10.3.2 Deals
12.1.11 BIOMERIEUX
12.1.11.1 Business overview
12.1.11.2 Products/Services offered
12.1.12 CYTONOME/ST, LLC
12.1.12.1 Business overview
12.1.12.2 Products/Services offered
12.1.13 SARTORIUS AG
12.1.13.1 Business overview
12.1.13.2 Products/Services offered
12.1.14 UNION BIOMETRICA, INC.
12.1.14.1 Business overview
12.1.14.2 Products/Services offered
12.1.15 TAKARA BIO INC.
12.1.15.1 Business overview
12.1.15.2 Products/Services offered
12.2 OTHER PLAYERS
12.2.1 APOGEE FLOW SYSTEMS LTD.
12.2.2 STRATEDIGM, INC.
12.2.3 NANOCELLECT BIOMEDICAL
12.2.4 BIOLEGEND, INC.
12.2.5 ON-CHIP BIOTECHNOLOGIES CO., LTD.
12.2.6 NEXCELOM BIOSCIENCE LLC
12.2.7 BENNUBIO INC.
12.2.8 ORFLO TECHNOLOGIES
12.2.9 BAY BIOSCIENCE LLC
12.2.10 CYTOBUOY

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS